Table 10.

Adverse events

ParameterMultitarget (n [%]; n = 20)Tacrolimus8,15 (n [%]; n = 35)MMF3,7 (n [%]; n = 43)
G-I syndrome2 (10.0)2 (5.7)8 (18.6)
Temporary GPT/GOT rise1 (5.0)3 (8.6)0 (0.0)
Transient increase in Scr0 (0.0)3 (8.6)0 (0.0)
Leucopenia2 (10.0)2 (5.7)1 (2.3)
New-onset hypertension3 (15.0)6 (17.1)0 (0.0)
Hyperglycemia1 (5.0)4 (11.4)0 (0.0)
Upper respiratory infection1 (5.0)1 (2.9)1 (2.3)
Pneumonia1 (5.0)1 (2.9)2 (4.7)
Herpes zoster or varicella1 (5.0)3 (8.6)2 (4.7)
Urinary tract infection1 (5.0)0 (0.0)0 (0.0)
Alopecia1 (5.0)5 (14.3)0 (0.0)
Irregular menstruation1 (5.0)1 (2.9)0 (0.0)